The number of beneficiaries eligible for the Medicare GLP-1 Bridge is unknown, but a previous KFF analysis estimated that close to 14 million Medicare beneficiaries had a diagnosis of overweight or obesity in 2020 (BMI of 25-29.9 and 30 or more, respectively), though applying the specific criteria that determine eligibility for the Medicare GLP-1 Bridge would reduce that number
Some benefits of FDA-approved GLP-1/GIP medications beyond weight loss are supported by emerging research and may vary based on individual health conditions, including: Improve blood sugar regulation, increase insulin sensitivity, and lower A1C Reduce long-term diabetic risks and protect pancreatic function Lower cholesterol, triglycerides, and blood pressure, supporting long-term cardiovascular health Show promising reductions in heart attacks and strokes in early studies Reduce liver fat and potentially improve metabolic fatty liver disease
Tirzepatide vs Retatrutide for Weight Loss When comparing pure weight loss potential, retatrutide currently appears to produce greater average reductions in body weight based on available research
J.MulpuriY.LeggioL.SpigelmanI
Take control of your gut health today
For some patients, compounded semaglutide offers more flexible dosing or a cost-conscious alternative while maintaining therapeutic benefits
